PediaBerry
Phase 1Small molecule
PediaBerry is one of 18 small molecule programs targeting Hemangioma. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
28 competitors in Hemangioma
#DrugCompanyPhaseTrials
1Inderal
WWyeth-Lederle Vaccines
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Timolol Maleate
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Aldara
BBausch Health Americas, Inc.
Approved
Zocor
OOrganon and Co
Approved
Medrol
PfizerPhase 3
Oncovin
Eli LillyPhase 2
Propanolol
WWeill Medical College of Cornell University
Phase 3
Rayos
RRoxane Laboratories
Phase 2
Propranolol Pill
UUniversity of Missouri-Columbia
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PediaBerry. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGayle Gordillo